Abbott Laboratories stock gains after FDA approval and strong guidance

Published on 09/09/2026 at 12:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock traded at USD 105.73 on September 9, 2026, while TD Cowen kept a Buy rating and a USD 135 target on September 8, 2026. Q2 sales reached USD 12.59 billion.

Modernes Diagnostik-Labor Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 zeigt modernes Diagnostik-Labor mit Wissenschaftlern in weißen Laborkitteln an Analysesystemen, Illustration mit AI erstellt.

Abbott Laboratories stock (ISIN US0028241000) traded at USD 105.73 on September 9, 2026, down 2.40 percent, after closing at USD 105.66 on September 8, 2026. TD Cowen kept a Buy rating and a USD 135 price target on September 8, 2026, while Abbott's latest quarter showed USD 12.59 billion in revenue and USD 1.31 in EPS.

FDA approval adds a catalyst

As StockTitan reported on September 8, 2026, Abbott received U.S. FDA approval for its TactiFlex Duo ablation catheter for atrial fibrillation. The approval gives the stock a fresh operating headline after a quarter in which revenue rose 13.0 percent year over year to USD 12.59 billion and EPS improved to USD 1.31 from USD 1.26.

The market also has a clear earnings frame: according to Yahoo Finance, the consensus for the current year is USD 5.52 EPS and USD 50.3 billion in revenue, with the next quarter modeled at USD 1.42 EPS and USD 12.99 billion in sales. That compares with year-ago sales of USD 44.33 billion and year-ago EPS of USD 5.15 for 2026 estimates.

Analysts stay constructive

According to GuruFocus on September 8, 2026, TD Cowen reiterated Buy on Abbott Laboratories and held the target at USD 135.00. In the same window, MarketBeat showed a consensus price target of USD 119.50, with the highest target at USD 143.00 and the lowest at USD 92.00.

For investors, the gap between the current quote and the analyst range matters more than the headline move. The stock changed hands at USD 105.73 on September 9, 2026, which leaves it below both TD Cowen's USD 135 target and the MarketBeat consensus of USD 119.50.

Price stays below targets

Abbott Laboratories stock traded at USD 105.73 on September 9, 2026, after a USD 105.66 close on September 8, 2026. The latest quarter and the FDA approval are the two numbers that now frame the next move.